Relmada Therapeutics Inc.

RLMD | NASDAQ

Price Alert Chart Builder DCF Calculator

$4.16

+$0.04 (+0.97%)

At close: Sep 21, 2026, 4:00 PM ET

$4.16

$0 (0.00%)

After-hours: Sep 21, 2026, 7:30 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+0.97%

(1D)

Rating

Updated: Aug 13, 2026

22.5

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $436.34M

1D Range

4.08 4.17

52W Range

1.47 8

Valuation (TTM)

PE -4.52

PB 2.11

EV/EBITDA -3.53

Valuation (NTM)

Forward PE N/A

Forward PEG -0.16

Price Target $12

Cash Flow

FCF Yield -14.0%

SBC Adj. FCF Yield -16.8%

SBC Impact -20.2%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y 48.8% | 41.0%

FCF 3Y | 5Y -12.1% | 17.0%

Returns

ROA -28.3%

ROE -47.5%

ROIC -30.8%

Financial Health

Net Cash

$217.73M

Current Ratio 29.52

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of g...

Sector Healthcare

Industry Biotechnology

Employees 17

IPO Date Jun 19, 2014

Website www.relmada.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$12

Upside

+188.46%

Buy (2)

Hold (0)

Sell (0)

Analyst Details ➞